Dr. Jumaa has over 21 years of experience in pharmaceutical product development, CMC, technology transfer, and preparing submissions to regulatory authorities from early development to commercial stage. He managed discovery pharmaceutics, pre-formulation and lead optimization, salt/form selection, formulation development, and commercial support, clinical packaging and labeling, clinical supplies management of all new oral, injectable, topical, and inhalation products. Dr. Jumaa co-invented and led the CMC efforts of Oprozomib and Kyprolis, from early discovery to approval & launch ( Kyprolis) coordinating multidisciplinary functions including API, Drug Product, Analytical, QA/QC. Dr. Jumaa authored over 20 scientific publications in peer-reviewed journals in the areas of IV/nano-emulsions, chemical stability, solubilization and formulation development, and inventor on multiple U.S. and international patents. Dr. Jumaa is a pharmacist in education and he received his Ph.D. in Pharmaceutical Technology from Kiel University-Germany followed by a post-doctoral fellowship in Pharmaceutical Chemistry from the University of Kansas.